75 related articles for article (PubMed ID: 1321186)
1. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.
Bevan EG; Connell JM; Doyle J; Carmichael HA; Davies DL; Lorimer AR; McInnes GT
J Hypertens; 1992 Jul; 10(7):607-13. PubMed ID: 1321186
[TBL] [Abstract][Full Text] [Related]
2. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
[TBL] [Abstract][Full Text] [Related]
3. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
Ansara AJ; Kolanczyk DM; Koehler JM
J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
[TBL] [Abstract][Full Text] [Related]
4. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.
Ruilope LM; Dukat A; Böhm M; Lacourcière Y; Gong J; Lefkowitz MP
Lancet; 2010 Apr; 375(9722):1255-66. PubMed ID: 20236700
[TBL] [Abstract][Full Text] [Related]
5. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.
Kostis JB; Packer M; Black HR; Schmieder R; Henry D; Levy E
Am J Hypertens; 2004 Feb; 17(2):103-11. PubMed ID: 14751650
[TBL] [Abstract][Full Text] [Related]
6. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II.
Richards AM; Wittert GA; Crozier IG; Espiner EA; Yandle TG; Ikram H; Frampton C
J Hypertens; 1993 Apr; 11(4):407-16. PubMed ID: 8390508
[TBL] [Abstract][Full Text] [Related]
7. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
Vardeny O; Miller R; Solomon SD
JACC Heart Fail; 2014 Dec; 2(6):663-70. PubMed ID: 25306450
[TBL] [Abstract][Full Text] [Related]
8. Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril.
Kaye B; Brearley CJ; Cussans NJ; Herron M; Humphrey MJ; Mollatt AR
Xenobiotica; 1997 Oct; 27(10):1091-102. PubMed ID: 9364744
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension.
Ogihara T; Rakugi H; Masuo K; Yu H; Nagano M; Mikami H
Am J Hypertens; 1994 Nov; 7(11):943-7. PubMed ID: 7848619
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction.
Mc Causland FR; Lefkowitz MP; Claggett B; Anavekar NS; Senni M; Gori M; Jhund PS; McGrath MM; Packer M; Shi V; Van Veldhuisen DJ; Zannad F; Comin-Colet J; Pfeffer MA; McMurray JJV; Solomon SD
Circulation; 2020 Sep; 142(13):1236-1245. PubMed ID: 32845715
[TBL] [Abstract][Full Text] [Related]
11. Impact of Sacubitril-Valsartan on Markers of Glomerular Function.
Tersalvi G; Dauw J; Martens P; Mullens W
Curr Heart Fail Rep; 2020 Aug; 17(4):145-152. PubMed ID: 32488503
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
Gu J; Noe A; Chandra P; Al-Fayoumi S; Ligueros-Saylan M; Sarangapani R; Maahs S; Ksander G; Rigel DF; Jeng AY; Lin TH; Zheng W; Dole WP
J Clin Pharmacol; 2010 Apr; 50(4):401-14. PubMed ID: 19934029
[TBL] [Abstract][Full Text] [Related]
13. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin.
Ando S; Rahman MA; Butler GC; Senn BL; Floras JS
Hypertension; 1995 Dec; 26(6 Pt 2):1160-6. PubMed ID: 7498988
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR;
N Engl J Med; 2014 Sep; 371(11):993-1004. PubMed ID: 25176015
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure.
Xu Y; Yang B; Hui J; Zhang C; Bian X; Tao M; Lu Y; Wang W; Qian H; Shang Z
Front Cardiovasc Med; 2023; 10():1125014. PubMed ID: 37273885
[TBL] [Abstract][Full Text] [Related]
16. The Natriuretic Peptides for Hypertension Treatment.
Rubattu S; Gallo G
High Blood Press Cardiovasc Prev; 2022 Jan; 29(1):15-21. PubMed ID: 34727352
[TBL] [Abstract][Full Text] [Related]
17. Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin): A Potential New Therapy for Hypertension.
Alves-Lopes R; Montezano AC; Neves KB; Harvey A; Rios FJ; Skiba DS; Arendse LB; Guzik TJ; Graham D; Poglitsch M; Sturrock E; Touyz RM
Hypertension; 2021 Sep; 78(3):604-616. PubMed ID: 34304582
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of neprilysin with sacubitril without RAS blockage aggravates renal disease in Dahl SS rats.
Polina I; Spicer MJ; Domondon M; Schibalski RS; Sarsenova E; Sultanova RF; Ilatovskaya DV
Ren Fail; 2021 Dec; 43(1):315-324. PubMed ID: 33541194
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin Receptor and Neprylisin Inhibitor: A new drug in pediatric cardiologist's armamentarium.
Arya A; Azad S; Sitaraman R
Ann Pediatr Cardiol; 2020; 13(4):334-336. PubMed ID: 33311922
[TBL] [Abstract][Full Text] [Related]
20. Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?
Salazar J; Rojas-Quintero J; Cano C; Pérez JL; Ramírez P; Carrasquero R; Torres W; Espinoza C; Chacín-González M; Bermúdez V
Curr Cardiol Rev; 2020; 16(1):25-35. PubMed ID: 31241018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
